Today: 20 June 2026
ASML stock dips on ex-dividend day as Europe’s €2.5 billion NanoIC chip line spotlights High-NA EUV
9 February 2026
1 min read

ASML stock dips on ex-dividend day as Europe’s €2.5 billion NanoIC chip line spotlights High-NA EUV

Amsterdam, February 9, 2026, 13:44 CET — Regular session on tap.

  • Shares of ASML (ASML.AS) slipped roughly 0.9% in Amsterdam after going ex-dividend.
  • Europe’s imec has launched its €2.5 billion “NanoIC” pilot line. ASML stands out as the biggest private backer, and a High-NA EUV tool is slated to arrive in March.
  • Investors are watching for U.S. data this week and keeping an eye on the upcoming report on AI-related chip demand.

ASML Holding dropped roughly 0.9% to 1,182.60 euros in Amsterdam trading Monday, moving lower as the Dutch chip equipment giant went ex-dividend. Shares finished Friday at 1,193.80 euros. Monday’s range landed between 1,177.40 and 1,204.40 euros.

Shares lose the next payout once they go ex-dividend. ASML announced an interim dividend of 1.60 euros a share, scheduled for payment on Feb. 18. The Nasdaq-listed stock trades ex-dividend on Feb. 10, which is also the record date, according to the company.

ASML shares were in focus after Belgium’s imec launched its 2.5 billion-euro “NanoIC” pilot line, a project rolled out under the EU Chips Act aiming to boost Europe’s slice of the semiconductor market to 20% by 2030. The initiative is receiving 1.4 billion euros in public money plus 1.1 billion from private investors—ASML being the biggest player on the private side. Imec is set to get ASML’s High-NA EUV tool in March. “We are all very proud and thankful that this is happening at the heart of Europe,” said ASML CEO Christophe Fouquet. Imec CEO Luc Van den hove called the new line “crucial” for Europe as AI takes off. Reuters

ASML’s high-NA EUV machines represent the next step forward in extreme ultraviolet lithography, pushing patterning on silicon to even finer scales. This ramp-up is critical—it’s aimed at sub-2-nanometre chip production, so any hiccups or hold-ups could disrupt fab construction plans and tool demand down the line.

Chip stocks outside Europe remained volatile. On Monday, Wall Street futures edged lower, with traders eyeing tech giants’ AI investment plans and bracing for U.S. payroll numbers on Wednesday, followed by inflation data Friday. Nvidia’s results, expected later this month, cast a shadow over the chip sector. “I’m not surprised … futures are down,” said Ipek Ozkardeskaya, senior market analyst at Swissquote Bank. Reuters

Dividend moves can cloud the tape for a session or more. What matters for ASML: customer spending, delivery timing—those will tell the real story, especially as the broader AI trade either calms or stays jumpy.

ASML leads the lithography market. Downstream, Applied Materials, Lam Research, and Tokyo Electron provide gear for other stages of chip production. Slowdowns in new fab projects tend to ripple through the whole group—not just a single supplier.

Up next on the corporate schedule: ASML’s annual report lands Feb. 25, with Q1 results slated for April 15.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • NovoCure Stock Falls 20% After TRIDENT Phase 3 Trial Miss, Valued 45.2% Below Fair Price
    June 20, 2026, 4:42 PM EDT. NovoCure (NVCR) shares plunged 20% after topline Phase 3 TRIDENT trial results showed starting Tumor Treating Fields therapy earlier failed to significantly improve survival in newly diagnosed glioblastoma patients. Despite this setback, NovoCure trades at $14.28, about 45.2% below an estimated fair value of $26.07, based on projected revenue growth and margin expansion from pipeline therapies in pancreatic and lung cancer. The market reaction reflects concern over near-term clinical and reimbursement hurdles, but optimism remains for longer-term regulatory approvals and market expansion from 2026. Investors face risks from trial outcomes and reimbursement delays, tempered by potential upside if NovoCure scales its core technology across multiple cancer indications.

Latest articles

Dell closes out short week with gains, AI server push stays in view

Dell closes out short week with gains, AI server push stays in view

20 June 2026
Dell closed at $409.50 on June 18, up about 3.5% from June 12, as investors focus on its booming AI server business after record Q1 results and a raised fiscal 2027 revenue outlook, with $24.4 billion in AI orders and a new quarterly dividend declared; all eyes now turn to the June 25 annual meeting amid ongoing risks from supply chain, demand, and tech sector volatility.
Palantir trades into the week as France move puts AI at risk in Europe

Palantir trades into the week as France move puts AI at risk in Europe

20 June 2026
Palantir faces a multi-year loss of its French DGSI contract to ChapsVision as France pushes for sovereign tech, casting uncertainty over its international government business even as U.S. revenue surges and the stock closed at $128.47, down 1.65% on June 18; investors eye risks if more European governments follow suit.
Windows 11 printer alert: Microsoft tightens the screws on legacy V3/V4 drivers in 2026
Previous Story

Windows 11 printer alert: Microsoft tightens the screws on legacy V3/V4 drivers in 2026

QVC Group stock (QVCGA) plunges on creditor-talks report as bankruptcy risk comes into view
Next Story

QVC Group stock (QVCGA) plunges on creditor-talks report as bankruptcy risk comes into view

Go toTop